-
immunotherapy using cutting-edge protein engineering with directed evolution. The lab has developed therapeutics that are currently in clinical trials, such as ST-067 (a "decoy-resistant" IL-18), MDNA-11 (CD122
-
provide fresh tumor specimens and PDX models, novel engineered murine models, state of the art-AI-enabled drug screening in microtumors and cancer cells, and more. Responsibilities The Clurman lab is
-
website provides additional information: https://research.fredhutch.org/haffner/en.html Responsibilities The particular areas of emphasis for this position center on studies of resistance to current
-
provides additional information: Peter Nelson Lab Responsibilities The particular areas of emphasis for this position center on studies of resistance to current therapeutics deployed to treat advanced cancer